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Abstract
Gestational diabetes mellitus (GDM) is an important risk factor for pregnancy complications. Since 2012, the Federal 
Joint Committee’s maternity directive recommends a two-step screening for GDM with a pre-test and subsequent diagnostic 
test if the pre-test is positive. This study analyses the implementation and development over time of GDM screening 
participation and prevalence in Germany. The data basis is the external inpatient obstetrics quality assurance documentation, 
which covers all births in hospital. Women with diabetes before pregnancy were excluded. The study defined women as 
GDM cases if the condition was documented in maternity records or if the ICD-10 diagnosis O24.4 was coded for 
inpatients at discharge and figures were determined for the years 2013 to 2018. As the documentation of screening tests 
has only been included in the data set since 2016, screening participation for the years 2016 to 2018 were estimated and 
evaluated based on the pre-test and/or diagnostic tests documented in maternity records. In 2018, the majority of all 
women who gave birth in hospitals had had a pre-test conducted (65.0%) or a pre-test and diagnostic test (18.2%) in 
line with the two-step procedure. A further 6.7% received a diagnostic test alone. GDM screening participation increased 
over time from 83.4% in 2016 to 89.9% in 2018. The prevalence of a documented GDM increased from 4.6% to 6.8% 
between 2013 and 2018. In 2018, this equates to 51,318 women with GDM. Reliably assessing the extent and causes of 
this development will require continuous analyses of screening implementation, documentation and changes in maternal 
risk factors.
 GESTATIONAL DIABETES · EPIDEMIOLOGY · SCREENING · PRENATAL CARE · DIABETES MELLITUS
1. Introduction
Gestational diabetes mellitus (GDM) is defined as a disor-
der of glucose tolerance occurring for the first time during 
pregnancy (Info box 1). GDM is one of the most common 
pregnancy complications and can have acute and long-term 
consequences for mother and child [1]. During pregnancy, 
GDM increases the risk of pre-eclampsia (a serious disease 
of the second half of pregnancy associated with high blood 
pressure, increased protein excretion in the urine and water 
retention), premature birth and caesarean section [2, 3]. 
Newborns of mothers with GDM are more likely to show 
malformations and high birth weight (macrosomia) [2, 3], 
which is associated with an increased incidence of birth 
injuries and shoulder dystocia [4]. In the long term, mothers 
with GDM have a significantly elevated risk of developing 
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type 2 diabetes [5] and subsequently also increased mor-
tality from cardiovascular disease [6].
According to estimates by the International Diabetes 
Federation, the prevalence of GDM ranges from 2% to over 
30% worldwide [7]. Even within Germany, prevalence esti-
mates of GDM vary considerably depending on the data 
source, study region and diagnostic criteria applied, and 
range between 5.1% and 13.2% [8–12]. International com-
parisons are complicated by diverging screening methods, 
diagnostic criteria and documentation systems [1, 13]. Con-
sistently, an increase in the prevalence of GDM has been 
observed in most countries over the last decades [14]. Dif-
ferent factors have potentially contributed to this develop-
ment, including changes to screening implementation and 
in the completeness of test result documentation [15] but 
also an increasing prevalence of important GDM risk fac-
tors such as obesity and advanced maternal age [1, 16]. 
Since 2012, pregnant women in Germany without pre-ex-
isting diabetes mellitus have been offered a two-step 
screening (Info box 2) for GDM based on the maternity 
directive of the Federal Joint Committee (G-BA) [17]. If ges-
tational diabetes is diagnosed, the pregnant woman should 
make an appointment with a diabetologist, who will inform 
her about GDM and advise her on therapy options. The 
primary treatment consists of adjusting diet and exercise 
habits while regularly measuring blood glucose [18]. Insu-
lin therapy is recommended for those women whose blood 
glucose levels do not return to normal with lifestyle changes. 
In order to report the disease dynamics and determi-
nants of diabetes mellitus in Germany on a recurring basis, 
a set of 40 indicators was defined within the framework of 
the diabetes surveillance at the Robert Koch Institute, which 
include risk factors, the disease frequency, care and the 
social impact of diabetes [19]. Within this framework GDM 
prevalence and screening participation are two core indi-
cators, as GDM represents an important risk factor for 
developing type 2 diabetes later in life [20]. Since 2015, the 
Institute for Quality Assurance and Transparency in Health 
Care (Institut für Qualitätssicherung und Transparenz im 
Gesundheitswesen, IQTIG) administrates the inpatient 
quality assurance data for obstetrics, which are made avail-
able on request for research purposes within the framework 
of secondary data use since 2019. These contain the details 
from the maternity records of all women who gave birth in 
hospital and information on inpatient stay, including the 
diagnosis at discharge. Based on this data source, the 
present study estimates the development of screening 
participation and the prevalence of GDM in Germany over 
time. In addition, the implementation and results of two-
step testing are evaluated in detail.
2. Methodology
2.1 Obstetrics data
Data from quality assurance procedures pursuant to Sec-
tion 136 of the German Social Code (Sozialgesetzbuch, 
SGB) V of the Federal Joint Committee (Gemeinsamer Bun-
desausschuss, G-BA) were used for this study. According 
to the G-BA’s directive on data-supported cross-facility qual-
ity assurance, all hospitals licensed under Section 108 of 
SGB V regularly submit measurement data on the quality 
of care with the aim of ensuring and promoting the quali-
ty of medical care [24]. In 2001, a corresponding quality 
assurance procedure was established for the field of 
Info box 1  
Gestational diabetes
Gestational diabetes mellitus belongs to the group 
of diabetes mellitus related metabolic diseases. 
Gestational diabetes is defined as a glucose intol-
erance occurring for the first time during pregnan-
cy and typically returning to normal after birth. Ges-
tational must be distinguished from manifest type 
1 or type 2 diabetes diagnosed for the first time dur-
ing pregnancy. Hormonal changes during pregnan-
cy lead to changes in insulin requirement, especial-
ly from the second trimester of pregnancy onwards. 
The decreased sensitivity of body cells to the hor-
mone insulin (insulin resistance) can lead to an 
increase in blood sugar levels. Early diagnosis and 
treatment can reduce the pregnancy and birth relat-
ed risks for mother and child resulting from gesta-
tional diabetes [3]. 
For this reason, Germany introduced general screen-
ing for gestational diabetes in 2012. According to 
the maternity directive of the Federal Joint Commit-
tee, screening is carried out in a two-step procedure 
and must be offered to pregnant woman between 
the 24th and 28th week of pregnancy [17]. First, a 
pre-test with 50 g glucose (glucose challenge test, 
GCT) is carried out, which can be performed regard-
less of the time of day and recent food intake. If the 
blood glucose value in the preliminary test exceeds 
135 mg/dL (7.5 mmol/L), a diagnostic test with 75 g 
glucose (oral glucose tolerance test, oGTT) follows, 
for which the pregnant woman has to fast. If the pre-
test exceeds the value of 200 mg/dL (11.1 mmol/L) 
then the woman has a manifest diabetes mellitus. 
In line with international guidelines, German guide-
lines for gestational diabetes nonetheless recom-
mend a diagnostic test directly, which is not covered 
by statutory health insurance [18].
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the data set from 2016 onwards following a decision by the 
G-BA to document them in maternity records in April 2014 
[27]. The information on pre-tests and the diagnostic tests 
is contained in catalogue B of the maternity record and 
registered under ‘Special findings during pregnancy’. The 
physician attending the pregnant woman enters in the 
maternity record whether a preliminary test and a diagnos-
tic test were carried out (yes/no) and whether the test was 
abnormal (yes/no). 
2.3 Definition of gestational diabetes
Cases of GDM were defined as GDM documented in the 
maternity record or the coding of GDM in the discharge 
diagnoses of the hospital stay at birth. In the maternity 
record, GDM is documented in catalogue B under ‘Spe-
cial findings during pregnancy’ by the physician who made 
the diagnosis of GDM. Discharge diagnoses are coded 
according to the International Statistical Classification of 
Dis eases and Related Health Problems, 10th Revision, Ger-
man Modification (ICD-10-GM [28]). GDM was assumed 
for the ICD-10 diagnosis O24.4. 
2.4 Statistical analyses
All data used to calculate GDM screening participation 
and prevalence were provided in aggregated format by 
the IQTIG stratified by reporting year and maternal age 
using the following age groups: <20 years, 20 to 24 years, 
25 to 29 years, 30 to 34 years, 35 to 39 years, 40 to 44 years 
and 45 years and older. To calculate GDM prevalence, a 
quotient was formed per age group and reporting year 
obstetrics (becoming part of the quality assurance proce-
dure perinatal medicine in 2021) covering all hospital births 
[11]. IQTIG currently compiles the data and ensures the 
quality assurance procedures. Secondary data use has been 
possible upon request and after approval by the G-BA for 
external applicants since 2019. Applicants receive the 
requested results in the form of aggregated data. The 
obstetrics dataset consists of two sub-datasets with infor-
mation on mothers (16/1:M) and on newborn children 
(16/1:K). In addition to demographic information on preg-
nant women, the dataset includes information on the 
course of pregnancy, birth and the newborn child. Informa-
tion on the course of pregnancy is mainly based on mater-
nity record logs. Hospitals transmit the data to the IQTIG 
using a standardised documentation form with the data 
collected during birth at the hospital [25].
The present study relies on data collected during the 
reporting years 2013 to 2018. Women diagnosed with dia-
betes before becoming pregnant (pre-conceptional diabe-
tes) and where this was documented in the maternity record 
at the first screening in catalogue A were excluded (Annex 
Figure 1). To assess completeness, the obstetric data were 
compared with the number of births published by the Fed-
eral Statistical Office [26]. Since the Federal Statistical Office 
only publishes the number of newborns, the total number 
of births was estimated using the number of live and still-
born children and the number of multiples for each year.
2.2 Definition of screening participation
The evaluation of screening tests was limited to the report-
ing years 2016 to 2018, as tests have only been included in 
Info box 2  
Screening
Screening is defined as the routine examination of 
persons without symptoms of disease for the pres-
ence of disease. The aim is to identify people at high 
risk of a particular disease and to diagnose the dis-
ease as early as possible [21]. The basic idea behind 
this is that starting treatment at an earlier stage of 
the disease improves the results of treatment. A well-
known example is mammography screening, which 
aims to detect breast cancer as early as possible [22]. 
The disadvantages of screening that have been dis-
cussed are false positive findings and disease stages 
that do not necessarily require treatment, which in 
turn can lead to health burdens, unnecessary thera-
pies and an unfavourable cost/benefit ratio [23].
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year, figures deviated between 2.5% and 3.6% (Annex 
Table 1). Deviations are owed to births outside the hos-
pital as well as to women with pre-conceptional diabetes, 
a condition found in around 1% of the women who gave 
birth in hospital each year (Annex Figure 1). Birth num-
bers have increased since 2013 to more than 750,000 
births in 2018 (Table 1). Over a third of mothers gave 
birth between the ages of 30 and 34. While the propor-
tion of births in the 20 to 24 age group has decreased, 
the proportions in the 30 to 34 and 35 to 39 age groups 
have increased over time. 
3.2 Gestational diabetes screening participation
Figure 1 shows the proportion of women with a hospital 
birth for the years 2016 to 2018 who received a pre-test and 
diagnostic test, only a diagnostic test, only a pre-test or no 
test. For the reporting year 2018, no information was avail-
able for 2.0% of women (missings), with no differences in 
the age distribution of women with documented screen-
ings. Over time, there was a decrease in the proportion of 
with the number of hospital births presenting maternal 
GDM according to the definition as numerator and all 
hospital births after excluding women with pre-concep-
tional diabetes as denominator. The screening participa-
tion was calculated analogously, excluding women with 
missing information on screening tests. For the screening 
participation, the results were analysed differentiated 
according to the test procedures performed (‘pre-test 
only’, ‘diagnostic test only’, ‘pre- and diagnostic test’ and 
‘no test’). In addition, age-standardised values of GDM 
prevalence were calculated based on the mentioned age 
groups. The age distribution of the study population from 
the reporting year 2018 was used as the reference popu-
lation (Table 1).
3. Results 
3.1 Description of the study population
A comparison of the number of hospital births with the 
birth figures of the Federal Statistical Office shows a high 
degree of completeness. Depending on the reporting 
Table 1 
Description of the study population – women 
with hospital births (n=4,303,532)
Source: External inpatient quality assurance 
for obstetrics at IQTIG, own calculations
2013 2014 2015 2016 2017 2018
n % n % n % n % n % n %
Study population 652,479 100 684,163 100 707,995 100 752,040 100 754,082 100 752,773
Age group
<20 years 14,508 2.2 14,723 2.2 15,218 2.1 17,125 2.3 15,085 2.0 14,059 1.9
20–24 years 79,407 12.2 77,888 11.4 77,214 10.9 81,503 10.8 77,886 10.3 76,152 10.1
25–29 years 184,419 28.3 193,496 28.3 201,817 28.5 212,031 28.2 209,148 27.7 203,621 27.0
30–34 years 227,597 34.9 241,715 35.3 249,698 35.3 263,024 35.0 268,134 35.6 271,545 36.1
35–39 years 119,093 18.3 128,014 18.7 135,413 19.1 147,513 19.6 151,879 20.1 154,683 20.5
40–44 years 26,074 4.0 26,877 3.9 27,084 3.8 29,142 3.9 30,180 4.0 30,923 4.1
≥45 years 1,381 0.2 1,450 0.2 1,551 0.2 1,702 0.2 1,770 0.2 1,790 0.2
Maternity records show that 
the proportion of women 
who gave birth in hospital 
without a screening for 
gestational diabetes during 
pregnancy decreased from 
16.6% in 2016 to 10.1%  
in 2018.
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By age group, the highest figure for women who were not 
tested (19.2%) is found in the age group under 25 (Figure 2). 
Between the ages of 25 and 44, the proportion is relatively 
constant at around 10% and then increases slightly for 
women aged 45 and older. In the age groups under 35, two 
thirds of women with a hospital birth receive only a pre-
test, while only half of women aged 45 and older receive 
only a pre-test. The proportion of women who have both 
tests or only a diagnostic test increases significantly with 
age. Age-specific distribution patterns are constant over 
the reporting years (Annex Table 2), meaning that the 
decline in the proportion of women without a test cannot 
be attributed to a specific age group. 
Maternity records document test procedures as well 
as test results. For the ‘pre-test only’ group, the pre-test 
result, for the other two tested groups the result of the 
diagnostic test was considered (Table 2). In the ‘pre-test 
only’ group, between 2016 and 2018, over 97% of the 
tested pregnant women consistently tested negative and 
thus were not affected by GDM. About 3% of the ‘pre-
test only’ group were positive and just under a quarter 
of them were also diagnosed as GDM. For the groups of 
pregnant women who received pre-test plus diagnostic 
test or only a diagnostic test, the proportion of positive 
tests increased from 25.7% to 37.6% and from 13.9% to 
17.6% respectively between 2016 and 2018. For all three 
tested groups, the proportion of positive tests increases 
significantly with age, and is highest (56.6%) for women 
in the ‘pre-test plus diagnostic test’ group aged 45 and 
older (Annex Table 3). 
women who were not screened and a corresponding 
increase in the proportion with screening results to 89.9% 
in 2018. While the proportion of women who gave birth in 
hospital and had only a diagnostic test performed remained 
relatively constant, figures for women with only a pre-test 
increased over time.
Figure 1 
Development of the proportion of women with 
hospital births according to the test procedure 
used during pregnancy (n=2,243,518) 
Source: External inpatient quality assurance 









No test Diagnostic test only
Pre-test only Pre- and diagnostic test
* In the reporting year 2018, 15,372 women with hospital births
  (2.0%) were excluded due to missing values (missings)
Figure 2 
Proportions of women with hospital births in 
2018* by test procedure used in pregnancy and 
age at birth of child (n=737,401) 
Source: External inpatient quality assurance 









<20 20–24 30–34 35–39 40–44 ≥45
No test Diagnostic test only
Pre-test only Pre- and diagnostic test
* In the reporting year 2018, 15,372 women with hospital births (2.0%) were excluded due
  to missing values (missings)
18.2% of women who  
gave birth in hospital had  
a pre-test and diagnostic test 
for gestational diabetes, 
65.0% a pre-test only and 
6.7% a diagnostic test only 
in 2018.
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29,735 to 51,318 women with GDM in the observation peri-
od. The increase in GDM prevalence affects all age groups 
meaning that the age-standardised prevalences are only 
slightly higher.
Most women diagnosed with GDM have had both a 
pre-test and a diagnostic test performed. Thus, in the 
reporting year 2018, 75.4% of the women with GDM were 
in the group ‘pre-test and diagnostic test’ and 12.3% in the 
‘diagnostic test only’ group. The remaining women received 
either only a pre-test (10.3%) or no test (2.0%). Between 
2016 and 2018, there was a slight decrease in the group 
without documented testing from 3.5% to 2.0%, which was 
accompanied by an increase in the group ‘pre-test and 
diagnostic test’.
Comparing the proportion of women with a positive 
diagnostic test and with documented GDM shows that the 
proportion of women with a positive diagnostic test is 
higher. While 6.8% had a positive diagnostic test in 2016, 
this proportion increased to 7.9% in 2018, 1.5 and 1.1 per-
centage points higher than the proportion with docu-
mented GDM. 
3.3 Prevalence of gestational diabetes
Documented GDM prevalence figures show a continuous 
increase from 4.6% in 2013 to 6.8% in 2018 (Table 3). 
Combined with the simultaneous increase in the total 
number of births, this translates to an increase from 
Table 2 
Absolute and relative proportion of women who 
gave birth in hospitals and screening for gesta-
tional diabetes by test method, test result and 
reporting year (n=1,948,847)
 Source: External inpatient quality assurance for 
obstetrics at IQTIG, own calculations
Screening GDM 2016 2017 20181
n % n % n %
Pre-test only2 403,086 476,489 479,277
Positive 11,556 2.9 14,004 2.9 13,629 2.8




Positive 7,443 13.9 7,926 17.1 8,694 17.6
Negative 45,926 86.1 38,523 82.9 40,586 82.4
Pre-test plus  
diagnostic test3
170,812 135,570 134,515
Positive 43,955 25.7 46,488 34.3 50,535 37.6
Negative 126,857 74.3 89,082 65.7 83,980 62.4
GDM = Gestational diabetes
1  In the reporting year 2018, 15,372 women with hospital births (2.0%) were 
excluded due to missing values (missings)
2  Test result refers to pre-test with 50 g glucose (glucose challenge test)
3  Test result refers to diagnostic test with 75 g glucose (oral glucose tolerance 
test, oGTT)
Table 3 
Age-specific prevalence of documented gesta-
tional diabetes in women with hospital births 
by reporting year (n=4,303,532)
Source: External inpatient quality assurance for 
obstetrics at IQTIG, own calculations
2013 2014 2015 2016 2017 2018
n % n % n % n % n % n %
GDM diagnosis 29,735 4.6 31,400 4.6 36,016 5.1 40,065 5.3 45,632 6.1 51,318 6.8
Age group
<20 years 238 1.6 232 1.6 265 1.7 310 1.8 373 2.5 358 2.5
20–24 years 2,232 2.8 2,182 2.8 2,232 2.9 2,673 3.3 2,915 3.7 3,275 4.3
25–29 years 7,119 3.9 7,336 3.8 8,490 4.2 9,459 4.5 10,300 4.9 11,581 5.7
30–34 years 10,865 4.8 11,330 4.7 13,098 5.2 14,427 5.5 16,501 6.2 18,518 6.8
35–39 years 7,164 6.0 7,941 6.2 9,231 6.8 10,409 7.1 12,131 8.0 13,584 8.8
40–44 years 1,981 7.6 2,215 8.2 2,511 9.3 2,608 8.9 3,161 10.5 3,718 12.0
≥45 years 136 9.8 164 11.3 189 12.2 179 10.5 251 14.2 284 15.9
GDM = Gestational diabetes
50,000 cases of gestational 
diabetes were documented 
in Germany among women 
with hospital births in 2018.
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during pregnancy [12]. The present study suggests that this 
proportion has further increased over time and that screen-
ing also reaches women covered by private health insur-
ance. In both studies, more than three quarters of pregnant 
women participated in the two-step screening. With age, 
the proportion of women who take both the pre-test and 
the diagnostic test increases significantly, which is because 
the age of the mother at birth is an important gestational 
diabetes risk factor. Only a small proportion of women 
receive a diagnostic test alone, which is somewhat higher 
in the present analysis (6.7% against 4.8%). 
Estimates on the prevalence of gestational diabetes in 
Germany vary considerably depending on the data source, 
4. Discussion
This study is the first to estimate the development of the doc-
umented screening participation and prevalence of gestation-
al diabetes in Germany using data from inpatient obstetric 
quality assurance. Most recently, 89.9% of pregnant women 
took part in screening and the proportion without testing has 
decreased significantly since 2016. Since the introduction of 
screening in 2012, there has been a steady increase in GDM 
prevalence and in 2018, 6.8% of women who gave birth in 
hospital had GDM documented in their maternity records. 
Analyses of outpatient claims data from 2014/2015 
already show that 80.8% of women were screened for GDM 
Source Data source Study population Definition GDM Number  
of cases




Survey and examination data 
from the University Women's 
Hospital Berlin
Women giving birth at the  
University Women's Hospital  
without pre-existing diabetes
Two-step test procedure
Screening with 50g CGT




Survey and examination  
data of the Rudolfstiftung 
Hospital
Pregnant women in weeks  
24 to 28 of gestation
Two-step test procedure
Screening with 1h 75g




Survey and examination data 
from the German Health 
Interview and Examination 
Survey for Children and  
Adolescents (KiGGS)
Mothers of participating children 
and young people
Information provided  





Survey and examination data 
from the Survey of Neonates 
in Pomerania (SNIP) study
Mothers of newborns Two-step test procedure 
Screening for glucosuria  




AOK Berlin claims data AOK-insured persons in Berlin with 
at least one year of insurance and 
pregnancy, excluding multiple  
pregnancies, multiple pregnancies 
within the study period, miscarriages 
and stillbirths, ectopic pregnancies 
and other diagnoses.
ICD-10 diagnosis: O24.4 





Data of the inpatient quality 
assurance obstetrics in Bavaria








Continued on next page
Table 4 
Overview of selected publications on the 
prevalence of gestational diabetes in Germany
Source: Own table
In relation to all women who 
gave birth in hospital, the 
prevalence of documented 
gestational diabetes in 
Germany rose steadily  
from 4.6% in 2013 to 6.8%  
in 2018.
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Table 4 Continued 
Overview of selected publications on the 
prevalence of gestational diabetes in Germany
Source: Own table
Source Data source Study population Definition GDM Number  
of cases




Outpatient claims data of KV 
Nordrhein
SHI-insured persons in KV Nord-
rhein with pregnancy in at least one 
quarter
ICD-10 diagnosis: O24.4 










Outpatient claims data of all 
KVs in Germany
SHI-insured persons nationwide 
with pregnancy in at least three 
quarters and no diabetes in two 
quarters before (ICD-10 diagnosis: 
E10–E14 or O24.0–O24.3)
ICD-10 diagnosis: O24.4, 
O24.9
N=567,191 2014–2015 13.2%
KBV [34] Outpatient claims data of all 
KVs in Germany
SHI-insured persons nationwide 
with pregnancy in at least three 
quarters and no diabetes in two 
quarters before (ICD-10 diagnosis: 
E10–E14 or O24.0–O24.3)















TK-insured persons with childbirth 
in the reporting year and with con-
tinuous insurance one year before 
pregnancy. Pregnancy of at least 20 
weeks and GDM test (EBM 01776 
or 01777).
ICD-10 diagnosis: O24.4 
without presence of  
diabetes in the previous 
year (ICD-10 diagnosis: 








Data from the nationwide 
inpatient quality assurance  
in obstetrics at the AQUA 
Institute or IQTIG














































Data from the nationwide 
inpatient quality assurance of 
obstetrics at IQTIG
Women with hospital birth without 
pre-existing diabetes 
Entry in the maternity 
record or ICD-10  
diagnosis O24.4 at  



















* Year of publication, as observation period not specified 
AQUA Institute = Institute for Applied Quality Improvement and Research in Health Care, AOK = Allgemeine Ortskrankenkasse, ATC = Anatomical Therapeutic 
Chemical Classification System, CGT = Glucose Challenge Test, EBM = Einheitlicher Bewertungsmaßstab, GDM = Gestational Diabetes, ICD = International  
Statistical Classification of Diseases and Related Health Problems, IQTIG = Institute for Quality Assurance and Transparency in Health Care, KV = Association of 
Statutory Health Insurance Physicians, KBV = National Association of Statutory Health Insurance Physicians, oGTT = oral glucose tolerance test, SHI = Statutory 
health insurance, TK = Techniker Krankenkasse
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gestational diabetes from newly diagnosed manifest diabe-
tes. For example, in approximately 1% of cases, in addition 
to gestational diabetes (ICD-10 diagnosis O24.4), manifest 
diabetes (ICD-10 diagnosis: O24.0–O24.3 or E10–E14) was 
also newly documented during pregnancy [10, 12]. These 
cases were only excluded in GDM prevalence estimate cal-
culations in the analyses based on KV Nordrhein data [10]. 
Furthermore, in two studies that were based on claims data, 
a high proportion (44% and 33%, respectively) of women 
diagnosed with GDM received only a pre-test [12, 33], which 
only indicates GDM or diabetes if the result is highly abnor-
mal [18, 36]. In the present study, this proportion is much 
lower at 10% to 11% (data not shown). This may have con-
tributed to an overestimation of prevalence in claims data, 
leaving the magnitude of the discrepancy with the current 
analysis unexplained. An underestimation of prevalence by 
the present study cannot be ruled out either, as despite a 
documented positive diagnostic test result some women 
still did not receive a GDM diagnosis. The proportion of 
women with a positive diagnostic test result is 1 to 1.5 per-
centage points higher than GDM prevalence. More in-depth 
analyses should determine the extent to which this is due 
to incomplete documentation or also actually a diagnosis 
of new type 1 or type 2 diabetes.
Furthermore, subgroups of pregnant women with a par-
ticularly high or low GDM risk may not be being tested. An 
Austrian study concluded that women with a migration 
background took part in screening less frequently, but 
showed more frequent abnormal findings than women 
without a migration background [37]. The latter was also 
reported by a regional analysis of data from the AOK Ber-
lin [32]. In addition, an analysis of hospital births in Bavaria 
observation period and diagnostic criteria applied (Table 4). 
Population-based studies or cohort studies report a GDM 
prevalence of five to eight percent  [8, 9, 29, 30] and are 
clearly above the estimates based on inpatient quality 
assurance data collected at the same time [11, 31]. How-
ever, the latter have increased significantly over the last 
few years. Analyses of statutory health insurance claims 
data provide higher GDM prevalence estimates [12, 32–34]. 
In line with this study, the available time series analyses 
show an increase in GDM prevalence over time. Reliable 
estimates of GDM prevalence are necessary to assess the 
extent and causes of this development and thus the poten-
tial for prevention.
For this reason, it is important to consider the influence 
of different data sources and diagnostic criteria with regard 
to an under- or overestimation of GDM prevalence. Except 
for the analysis of data from the Association of Statutory 
Health Insurance Physicians of Nordrhein (KV Nordrhein) 
[10], the study population of all estimates refers to women 
who have given birth and thus excludes pregnant women 
who have suffered miscarriages (Table 4). The study based 
on 2017 outpatient claims data examined the largest study 
population to date with 75% of all births, but this only 
included women covered by statutory health insurance that 
received continuous outpatient care [12]. Furthermore, case 
definitions in the studies also differed significantly. In claims 
data and inpatient quality assurance data, the prevalence 
of GDM is estimated on the basis of documented diagno-
ses [10, 12, 32, 33] or corresponding logs in maternity records 
[11, 31, 35] whereas survey and examination studies used 
measurement results to determine GDM prevalence [8, 9, 
29, 30]. In claims data analyses, it is difficult to distinguish 
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set also facilitates the analysis of complications during 
birth depending on the presence of GDM.
Limitations and strengths
The data basis of the present study includes all hospital 
births irrespective of the mothers’ insurance status and 
covers 97% of all births in Germany. Births outside of hos-
pitals are not included, although the 2018 estimates for the 
prevalence of GDM here are significantly lower (1.3%) [43]. 
The selection bias for this study can be assumed to be low-
er than in cohort studies and analyses of claims data. 
Maternity records are the central source of information and 
have not only been documenting diagnosed cases of GDM, 
but also information on the results of pre-tests and diag-
nostic tests in the two-step screening procedure for GDM 
since 2014. Screening examinations will also document 
when a person does not have a test, whereas GDM tests 
will only document a positive result. In the maternity 
records of 90% of women who gave birth in hospital, 
whether they have received at least one of the two tests 
and with a positive or negative result is recorded. Howev-
er, inconsistent documentation such as a positive diagnos-
tic test without the diagnosis of GDM indicates limitations 
in the completeness and accuracy of the documentation. 
Thus, the proportion of women with a positive diagnostic 
test is 1 to 1.5 percentage points higher than the proportion 
of women with documented GDM and so an underestima-
tion of GDM is therefore possible. 
Conclusion
The data of inpatient obstetric quality assurance appears to 
be a suitable source for continuous surveillance of the 
showed that GDM prevalence is increased in socioeconom-
ically deprived regions, characterised, for example, by 
higher unemployment and lower income [35]. The correla-
tion was not evident before the introduction of general 
screening, so it can be assumed that especially women in 
regions with high social deprivation are reached by general 
screening. The inpatient quality assurance of obstetrics 
data set offers opportunities for further analyses regarding 
women who have not yet been reached by screening. In 
this case, regional differences and maternal risk factors for 
GDM can be specifically examined. A comparison between 
European countries is also difficult due to different diag-
nostic criteria [15, 38]. Countries with two-step GDM screen-
ing show lower prevalences than single test countries [39, 
40]. Similar to the development in Germany, GDM preva-
lence over time is rising in Europe [14]. This raises the ques-
tion as to the extent to which lifestyle factors such as obe-
sity or severe weight gain, physical activity and diet before 
and during pregnancy [1, 41] play a role, irrespective of the 
methodological differences that exist between countries, 
as these could offer starting points for measures to prevent 
gestational diabetes. In Israel, for example, a nine-item 
questionnaire was developed using machine learning meth-
ods capable of assessing women’s risk of developing ges-
tational diabetes already in early pregnancy [42]. Since the 
data set of inpatient obstetric quality assurance also con-
tains information on maternal risk factors such as body 
mass index, weight gain during pregnancy or smoking, it 
could in future, after confirming the reliability of the rele-
vant information, enable the use of innovative methods to 
detect women at increased risk of gestational diabetes, in 
line with the aforementioned study. Furthermore, the data 
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Annex Figure 1 
Flowchart for the analysis of gestational 
diabetes and the screening participation 
as an example for 2013
Source: Own figure




 gestational diabetes 
n=622,744
Study population for analysis 
n=652,479
Women with pre-conceptional 
diabetes excluded 
n=6,256
Hospital births in the obstetrics 
data set 
n=658,735
Annex Table 1 
Comparison of the number of births in the 
IQTIG inpatient obstetric quality assurance 
dataset and the Federal Statistical Office
Source: Federal Statistical Office – Statistics on 
births [26], External inpatient quality assurance 
for obstetrics at IQTIG, own calculations
2013 2014 2015 2016 2017 2018
Federal Statistical Office
Live-born 682,069 714,927 737,575 792,141 784,901 787,523
Stillborn 2,556 2,597 2,787 2,914 3,003 3,030
Multiples 12,355 13,270 13,637 14,635 14,712 14,365
Twins 12,119 12,977 13,368 14,371 14,415 14,099
Triplets 230 282 258 258 287 260
Higher grade multiples 6 11 11 6 10 6
Estimated births1 672,028 703,950 726,445 780,150 772,885 775,916
Inpatient quality assurance obstetrics
Births2 652,479 684,163 707,995 752,040 754,082 752,773
Difference
Absolutely 19,549 19,787 18,450 28,110 18,803 23,143
Relatively 2.9% 2.8% 2.5% 3.6% 2.4% 3.0%
IQTIG = Institute for Quality Assurance and Transparency in Health Care
1 Total live births and stillbirths – (number of twins + twice number of triplets + three times number of higher-grade multiples)
2 Women with pre-existing diabetes mellitus are excluded
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Annex Table 2 
Age-specific screening participation of pregnant 
women with hospital births by test procedure 
and reporting year (n=2,243,518) 
Source: External inpatient quality assurance 
for obstetrics at IQTIG, own calculations
Annex Table 3 
Proportion of positive screening tests by testing 
method used, reporting year and age of women 
at birth (n=1,948,847)
Source: External inpatient quality assurance 
for obstetrics at IQTIG, own calculations
2016 2017 2018*
n % n % n %
Pre-test only 403,086 53.6 476,489 63.2 479,277 65.0
Age group
<20 years 8,826 51.5 9,389 62.2 8,977 65.6
20–24 years 43,601 53.5 49,757 63.9 49,726 66.8
25–29 years 117,361 55.4 136,814 65.4 134,381 67.3
30–34 years 142,566 54.2 170,695 63.7 174,591 65.6
35–39 years 76,039 51.5 91,981 60.6 93,631 61.8
40–44 years 13,985 48.0 16,969 56.2 17,105 56.6
≥45 years 708 41.6 884 50.0 866 49.5
Diagnostic test 
only
53,369 7.1 46,449 6.2 49,280 6.7
Age group
<20 years 813 4.7 532 3.5 483 3.5
20–24 years 4,538 5.6 3,458 4.4 3,437 4.6
25–29 years 13,909 6.6 11,045 5.3 11,313 5.7
30–34 years 19,554 7.4 17,469 6.5 18,711 7.0
35–39 years 11,944 8.1 11,324 7.5 12,419 8.2
40–44 years 2,462 8.4 2,473 8.2 2,736 9.1
≥45 years 149 8.8 148 8.4 181 10.3
2016 2017 2018*
n % n % n %
Pre- and  
diagnostic test
170,812 22.7 135,570 18.0 134,515 18.2
Age group
<20 years 2,686 15.7 1,724 11.4 1,594 11.6
20–24 years 15,545 19.1 11,186 14.4 10,555 14.2
25–29 years 45,749 21.6 35,084 16.8 33,941 17.0
30–34 years 61,083 23.2 49,137 18.3 49,215 18.5
35–39 years 37,101 25.2 31,000 20.4 31,398 20.7
40–44 years 8,117 27.9 6,946 23.0 7,319 24.2
≥45 years 531 31.2 493 27.9 493 28.2
No test 124,772 16.6 95,570 12.7 74,329 10.1
Age group
<20 years 4,800 28.0 3,439 22.8 2,630 19.2
20–24 years 17,819 21.9 13,485 17.3 10,676 14.4
25–29 years 35,012 16.5 26,205 12.5 19,984 10.0
30–34 years 39,821 15.1 30,833 11.5 23,806 8.9
35–39 years 22,429 15.2 17,574 11.6 13,960 9.2
40–44 years 4,578 15.7 3,792 12.6 3,062 10.1
≥45 years 313 18.4 242 13.7 211 12.1
* In the reporting year 2018, 15,372 women with hospital births (2.0%) were excluded due to missing values (missings)
Pre-test only1 Diagnostic test only2 Pre- and diagnostic test2
2016 2017 2018* 2016 2017 2018* 2016 2017 2018*
Age group in percent
<20 years 2.1 2.0 2.2 7.9 11.4 9.9 14.7 21.7 23.4
20–24 years 2.5 2.7 2.3 10.4 13.5 13.8 19.3 26.9 30.0
25–29 years 2.6 2.6 2.6 11.7 14.9 15.8 22.6 30.3 33.6
30–34 years 2.8 2.9 2.8 13.6 16.5 16.6 25.4 33.7 36.9
35–39 years 3.4 3.5 3.3 17.2 19.8 20.5 31.0 40.0 43.1
40–44 years 4.2 4.4 4.7 21.7 24.1 25.6 36.9 46.7 50.0
≥45 years 4.4 6.1 6.7 26.0 25.8 26.5 44.4 51.7 56.6
Total 2.9 2.9 2.8 13.9 17.1 17.6 25.7 34.3 37.6
1 Test result refers to pre-test with 50g glucose (glucose challenge test, GCT)
2 Test result refers to diagnostic test with 75g glucose (oral glucose tolerance test, oGTT)
*  In the reporting year 2018, 15,372 women with hospital births (2.0%) were excluded due to missing values (missings)
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